Apimeds Pharmaceuticals Files S-1/A Amendment
Ticker: APUS · Form: S-1/A · Filed: Jan 29, 2025 · CIK: 1894525
| Field | Detail |
|---|---|
| Company | Apimeds Pharmaceuticals Us, INC. (APUS) |
| Form Type | S-1/A |
| Filed Date | Jan 29, 2025 |
| Risk Level | medium |
| Pages | 14 |
| Reading Time | 17 min |
| Key Dollar Amounts | $8.28, $20.24, $10.73, $24.4 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, s-1/a, pharmaceuticals, ipo-process
TL;DR
Apimeds Pharma filed an S-1/A amendment on Jan 29, 2025. Looks like they're still working on their public offering.
AI Summary
Apimeds Pharmaceuticals US, Inc. filed an S-1/A amendment on January 29, 2025, for its registration statement (No. 333-282324). The company, incorporated in Delaware and operating in the pharmaceutical preparations sector, has its principal executive offices at 2 East Broad Street, Hopewell, NJ. The filing indicates an amendment to a previous registration, suggesting ongoing efforts to go public or adjust existing public offerings.
Why It Matters
This filing is an update to Apimeds Pharmaceuticals' registration statement, indicating progress or changes in their plans to offer securities to the public, which could impact potential investors.
Risk Assessment
Risk Level: medium — As an S-1/A filing, it pertains to a company seeking to register securities, which inherently carries risks associated with early-stage or public offerings.
Key Numbers
- 333-282324 — SEC File Number (Identifies the specific registration statement being amended.)
- 20250129 — Filing Date (Date the amendment was submitted to the SEC.)
Key Players & Entities
- Apimeds Pharmaceuticals US, Inc. (company) — Registrant
- 2 East Broad Street, 2nd Floor, Hopewell, NJ 08525 (location) — Principal Executive Offices
- Erik Emerson (person) — Chief Executive Officer
- 333-282324 (document_id) — SEC File Number
- January 29, 2025 (date) — Filing Date
FAQ
What is the purpose of this S-1/A filing?
This is Amendment No. 5 to the Form S-1 Registration Statement, indicating updates or changes to the company's initial filing for securities registration.
Who is the Chief Executive Officer of Apimeds Pharmaceuticals US, Inc.?
Erik Emerson is listed as the Chief Executive Officer.
Where are Apimeds Pharmaceuticals US, Inc.'s principal executive offices located?
The principal executive offices are located at 2 East Broad Street, 2nd Floor, Hopewell, NJ 08525.
What is the SEC file number associated with this registration statement?
The SEC file number is 333-282324.
What industry does Apimeds Pharmaceuticals US, Inc. operate in?
The company operates in the Pharmaceutical Preparations sector, with SIC code 2834.
Filing Stats: 4,224 words · 17 min read · ~14 pages · Grade level 14.9 · Accepted 2025-01-29 16:41:15
Key Financial Figures
- $8.28 — the United States accounted for $8.28 billion in 2022 and it is expect
- $20.24 — n 2022 and it is expected to hit around $20.24 billion by 2032, expanding at a
- $10.73 — the United States accounted for $10.73 billion in 2022 and is expected
- $24.4 — ;billion in 2022 and is expected to hit $24.4 billion by 2030, expanding at a
Filing Documents
- ea0201124-13.htm (S-1/A) — 4026KB
- ea020112413ex5-1_apimeds.htm (EX-5.1) — 11KB
- ea020112413ex23-1_apimeds.htm (EX-23.1) — 2KB
- ea020112413ex24-2_apimeds.htm (EX-24.2) — 11KB
- ea020112413ex-fee_apimeds.htm (EX-FILING FEES) — 24KB
- tapimeds_logo.jpg (GRAPHIC) — 91KB
- tboral_logo.jpg (GRAPHIC) — 77KB
- ttable_01.jpg (GRAPHIC) — 994KB
- tflowchart_001.jpg (GRAPHIC) — 266KB
- ex5-1_001.jpg (GRAPHIC) — 9KB
- 0001213900-25-007894.txt ( ) — 6052KB
RISK FACTORS
RISK FACTORS   11 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS   48
USE OF PROCEEDS
USE OF PROCEEDS   51 REVERSE STOCK SPLIT   52 DIVIDEND POLICY   52 CAPITALIZATION   53
DILUTION
DILUTION   54 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS   56
BUSINESS
BUSINESS   66 MANAGEMENT   91
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION   98 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS   104 PRINCIPAL STOCKHOLDERS   108
DESCRIPTION OF CAPITAL STOCK
DESCRIPTION OF CAPITAL STOCK   110 SHARES ELIGIBLE FOR FUTURE SALE   112 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS   114
UNDERWRITING
UNDERWRITING   117 LEGAL MATTERS   125 EXPERTS   125 WHERE YOU CAN FIND MORE INFORMATION   125 INDEX TO FINANCIAL STATEMENTS   F-1 You should rely only on the information contained in this prospectus. We and the underwriters have not authorized any other person to provide you with information different from or in addition to that contained in this prospectus, and we take no responsibility for any other information others may give you. If anyone provides you with different or inconsistent information, you should not rely on it. We and the underwriters are not making an offer to sell these securities in any jurisdiction where an offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date. No action is being taken in any jurisdiction outside the United States to permit a public offering of our common stock or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus applicable to that jurisdiction. i Table of Contents PROSPECTUS SUMMARY This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our common stock. You should read this entire prospectus carefully, including the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and the related notes included elsewhere in this prospectus, before ma